Ipatasertib dihydrochloride

Ipatasertib dihydrochloride is an inhibitor of AKT1 and AKT2 and related targets used in studies of PI3K-Akt-mTOR Signaling. It is especially relevant in cancer, cell signaling, and metabolism models, where defined compound exposure can be linked to growth-factor signaling, survival control, and nutrient-sensing outputs.

By inhibiting AKT1 and AKT2 and related targets, Ipatasertib dihydrochloride can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell signaling, and metabolism models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving AKT1 and AKT2 and related targets
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Ipatasertib dihydrochloride is appropriate when a defined chemical perturbant is needed to connect AKT1 and AKT2 and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell signaling, and metabolism models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.